StocksRankings — AI Stock Picks & Rankings

AI Stock Picks — May 22, 2026

The 5 AI-selected stock picks for May 22, 2026 from StocksRankings — with full investment thesis, bull case, bear case, and key catalyst for each.

5 AI Stock Picks for May 22, 2026

  1. LAM — Lam Research [Top Performer]
    Lam Research, a leader in wafer fabrication equipment, is set to benefit from the ongoing ramp in advanced semiconductor manufacturing as highlighted by the upcoming SpaceX IPO and continued AI infrastructure buildout. The company’s core etch and deposition tools are essential for next-generation memory and logic nodes, with a 1-year return of +273.29% confirming sustained demand. The PEG ratio of 0.64 and strong free cash flow growth support further upside as capital spending remains robust.
    Key risk: A sharp pullback in semiconductor capex from major foundries could reduce equipment orders and pressure margins.
  2. EXPE — Expedia Group [Winner on a Dip]
    Expedia Group, a leading online travel platform, is trading at deeply oversold levels after sector rotation out of discretionary names despite robust free cash flow and a 36% 1-year return. The company’s platform scale and $7,543M in free cash flow enable continued investment in technology and marketing, supporting share gains as travel demand normalizes. An RSI of 25.9 and a PEG ratio of 0.35 indicate the stock is pricing in excessive pessimism, setting up for a rebound as sector sentiment stabilizes.
    Key risk: A prolonged slowdown in consumer travel spending due to persistent inflation could delay earnings recovery and compress multiples.
  3. ABBV — AbbVie [Lowest PEG]
    AbbVie, a global biopharmaceutical company, is positioned for earnings growth driven by new immunology and neuroscience launches as the sector rotates toward value and defensives. The company’s $19,980M in free cash flow and 654% EPS growth provide financial strength to support pipeline investments and dividends. The PEG ratio of 0.16 is among the lowest in the Nasdaq 100, indicating the market is undervaluing AbbVie’s forward growth relative to its peers.
    Key risk: Unexpected biosimilar competition or regulatory setbacks on key pipeline drugs could impair revenue growth.

See today's picks · full picks history · AI pick track record